StocksFundsScreenerSectorsWatchlists
WST

WST - West Pharmaceutical Services Inc Stock Price, Fair Value and News

378.51USD-1.49 (-0.39%)Delayed as of 15 Apr 2024, 02:53 pm ET

Market Summary

WST
USD378.51-1.49
Delayedas of 15 Apr 2024, 02:53 pm
-0.39%

WST Alerts

  • 1 major insider sales recently.

WST Stock Price

View Fullscreen

WST RSI Chart

WST Valuation

Market Cap

27.8B

Price/Earnings (Trailing)

46.92

Price/Sales (Trailing)

9.44

EV/EBITDA

32.19

Price/Free Cashflow

67.17

WST Price/Sales (Trailing)

WST Profitability

EBT Margin

23.66%

Return on Equity

20.6%

Return on Assets

15.5%

Free Cashflow Yield

1.49%

WST Fundamentals

WST Revenue

Revenue (TTM)

2.9B

Rev. Growth (Yr)

3.29%

Rev. Growth (Qtr)

-2.06%

WST Earnings

Earnings (TTM)

593.4M

Earnings Growth (Yr)

33.01%

Earnings Growth (Qtr)

-15.07%

Breaking Down WST Revenue

52 Week Range

330.16415.73
(Low)(High)

Last 7 days

-3.6%

Last 30 days

-1.5%

Last 90 days

9.5%

Trailing 12 Months

3.6%

How does WST drawdown profile look like?

WST Financial Health

Current Ratio

2.88

Debt/Equity

0.03

Debt/Cashflow

10.67

WST Investor Care

Dividend Yield

0.21%

Dividend/Share (TTM)

0.78

Buy Backs (1Y)

1.13%

Diluted EPS (TTM)

7.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.9B2.9B2.9B2.9B
20222.9B2.9B2.9B2.9B
20212.3B2.5B2.7B2.8B
20201.9B1.9B2.0B2.1B
20191.7B1.8B1.8B1.8B
20181.6B1.7B1.7B1.7B
20171.5B1.5B1.6B1.6B
20161.4B1.5B1.5B1.5B
20151.4B1.4B1.4B1.4B
20141.4B1.4B1.4B1.4B
20131.3B1.3B1.3B1.4B
20121.2B1.2B1.2B1.3B
20111.1B1.2B1.2B1.2B
20101.1B1.1B1.1B1.1B
200901.1B1.1B1.1B
20080001.1B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of West Pharmaceutical Services Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 11, 2024
winters chad
acquired
116,924
173
675
vp, chief accounting officer
Mar 11, 2024
winters chad
sold
-292,436
358
-815
vp, chief accounting officer
Feb 28, 2024
witherspoon charles
acquired
206,968
102
2,019
vp & treasurer
Feb 28, 2024
witherspoon charles
sold
-724,061
358
-2,019
vp & treasurer
Feb 27, 2024
green eric mark
sold
-23,078,000
359
-64,132
president, ceo and board chair
Feb 27, 2024
green eric mark
acquired
4,196,310
57.38
73,132
president, ceo and board chair
Feb 23, 2024
abraham silji
acquired
1,214,620
173
7,012
svp, chief technology officer
Feb 23, 2024
abraham silji
sold
-2,559,380
365
-7,012
svp, chief technology officer
Feb 20, 2024
abraham silji
acquired
-
-
646
svp, chief technology officer
Feb 20, 2024
winters chad
acquired
-
-
179
vp, chief accounting officer

1–10 of 50

Which funds bought or sold WST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 11, 2024
BRIGHT ROCK CAPITAL MANAGEMENT, LLC
unchanged
-
1,133,340
10,288,500
2.13%
Apr 11, 2024
City State Bank
reduced
-2.09
7,000
74,000
0.03%
Apr 11, 2024
CHURCHILL MANAGEMENT Corp
reduced
-1.07
450,718
4,480,640
0.06%
Apr 11, 2024
CONTRAVISORY INVESTMENT MANAGEMENT, INC.
reduced
-95.53
-561,531
29,678
0.01%
Apr 11, 2024
CONGRESS ASSET MANAGEMENT CO /MA
reduced
-0.09
14,194,600
129,845,000
0.93%
Apr 11, 2024
Opal Wealth Advisors, LLC
new
-
73,603
73,603
0.03%
Apr 11, 2024
Fortitude Family Office, LLC
unchanged
-
480
4,353
-%
Apr 11, 2024
Ballentine Partners, LLC
reduced
-4.19
19,989
280,558
-%
Apr 11, 2024
RFG Advisory, LLC
added
2.3
75,500
579,863
0.02%
Apr 11, 2024
ROCKLAND TRUST CO
added
0.77
2,426,450
20,748,700
1.09%

1–10 of 49

Are Funds Buying or Selling WST?

Are funds buying WST calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own WST
No. of Funds

Unveiling West Pharmaceutical Services Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.17%
9,002,632
SC 13G/A
Jan 24, 2024
blackrock inc.
10.5%
7,778,203
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
3.1%
2,301,161
SC 13G/A
Feb 09, 2023
vanguard group inc
12.14%
8,988,409
SC 13G/A
Jan 24, 2023
blackrock inc.
11.0%
8,148,624
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.4%
6,241,901
SC 13G/A
Feb 04, 2022
franklin resources inc
3.8%
2,848,869
SC 13G/A
Jan 27, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Jan 25, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Apr 12, 2021
blackrock inc.
10.1%
7,467,809
SC 13G/A

Recent SEC filings of West Pharmaceutical Services Inc

View All Filings
Date Filed Form Type Document
Mar 19, 2024
PX14A6G
PX14A6G
Mar 13, 2024
ARS
ARS
Mar 13, 2024
DEF 14A
DEF 14A
Mar 13, 2024
DEFA14A
DEFA14A
Mar 12, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
PRE 14A
PRE 14A
Feb 29, 2024
4
Insider Trading
Feb 27, 2024
144
Notice of Insider Sale Intent
Feb 27, 2024
4
Insider Trading

Peers (Alternatives to West Pharmaceutical Services Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
189.3B
40.1B
-9.21% 5.29%
33.08
4.72
-8.12% -17.45%
67.9B
19.5B
-1.55% -8.27%
54.08
3.48
4.02% -22.04%
23.7B
3.9B
-1.72% -7.67%
53.19
6.13
3.42% 23.09%
20.5B
14.8B
-5.55% -6.65%
7.71
1.38
2.12% 209.17%
MID-CAP
9.1B
12.3B
-5.72% -13.98%
21.94
0.74
-2.44% -22.68%
9.1B
3.5B
-2.81% 14.53%
31.84
2.6
4.97% 18.89%
8.8B
2.7B
-10.75% -38.18%
-13.76
3.28
-4.68% 82.43%
6.5B
4.0B
-8.29% -23.99%
-48.26
1.64
1.10% 85.84%
3.4B
366.4M
-0.38% 19.00%
-568.11
9.41
33.86% 89.83%
2.3B
6.6B
-5.95% -4.86%
11.79
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-4.92% -19.00%
-1.93
0.41
7.73% -1066.14%
371.2M
166.7M
-1.34% -7.94%
-4.49
2.23
6.67% -456.34%
255.1M
324.0M
14.75% -32.34%
-1.33
0.79
-3.19% -337.41%
50.6M
52.3M
-18.86% -53.44%
-2.7
0.97
17.61% 19.28%
4.0M
3.7M
-9.04% 297.37%
-0.32
1.06
5.77% 8.23%

West Pharmaceutical Services Inc News

Latest updates
Defense World10 hours ago
Sure Dividend26 Mar 202407:00 am

West Pharmaceutical Services Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-2.1%732747754717709687771720731707724671580548527492471456470444423
Gross Profit-3.5%278288291271262268322285301288315272211195195167153148158147133
  S&GA Expenses1.1%90.0089.0088.0086.0086.0066.0082.0083.0098.0092.0093.0080.0076.0076.0078.0072.0069.0065.0070.0069.0060.00
  R&D Expenses12.2%18.0016.0017.0017.0016.0014.0014.0015.0014.0013.0014.0012.0013.0013.0011.0011.0010.009.0010.0010.0010.00
EBITDA Margin4.6%0.29*0.27*0.26*0.27*0.28*0.30*0.31*0.31*0.31*0.30*0.28*0.26*0.24*--------
Interest Expenses-58.6%1.003.003.002.002.002.002.002.003.002.002.002.002.002.002.002.002.002.002.002.002.00
Income Taxes17.3%35.0029.0035.0024.0029.0020.0044.0021.0034.0012.0032.0029.0020.0021.0016.0015.0017.0011.0016.0016.0015.00
Earnings Before Taxes-10.1%16818718515812913622718818218121117511598.0010287.0077.0065.0080.0070.0066.00
EBT Margin5.2%0.24*0.23*0.21*0.23*0.24*0.25*0.27*0.26*0.26*0.25*0.24*0.21*0.19*--------
Net Income-15.1%13716115514010312118917414817618715198.0082.0091.0074.0064.0056.0066.0055.0052.00
Net Income Margin5.2%0.20*0.19*0.18*0.19*0.20*0.22*0.23*0.24*0.23*0.23*0.21*0.18*0.16*--------
Free Cashflow-2.9%13013494.0056.0013611110785.0084.0012588.0034.0091.00--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets2.0%3,8303,7553,6703,7243,6173,3173,3623,2953,3143,1432,9342,7402,7942,5832,3922,2472,3412,1742,1232,0361,979
  Current Assets-1.8%1,9361,9721,8741,9371,9201,7341,7711,6911,7421,5981,4771,3271,3741,2381,1119781,0591,004944868894
    Cash Equivalents-5.0%854899796886894729719668763688576484616519446335439396327266337
  Inventory0.7%435432449447415413412417378354345310321295275251236230232226215
  Net PPE7.8%1,4131,3121,2611,2151,1581,0691,0771,0661,0581,007973931943883840828839812823815822
  Goodwill1.6%109107108108107104107109110109110110111109108107108107108105106
Liabilities7.0%949887923947932846937969978940901911939864786756768686678667583
  Current Liabilities25.9%672534512535519457565585594559473483503448375344342335313301284
  Long Term Debt-52.1%73.00152206206207207208208209210252252253253254254255195196196196
    LT Debt, Non Current-52.1%73.00152206206207207208208209210252252253253254254255195196196196
Shareholder's Equity0.4%2,8812,8682,7472,7762,6852,4712,4242,3262,3352,2022,0331,8291,8551,7191,6061,4901,5731,4881,4451,3701,396
  Retained Earnings3.1%3,5233,4163,2553,1142,9882,9132,7932,6172,4572,3362,1601,9851,8471,7731,7031,6121,5491,4971,4531,3981,353
  Additional Paid-In Capital-2.0%120123158181232231225220249251248247267268263268273269273279282
Accumulated Depreciation2.3%1,3251,2961,2821,2641,2281,1641,1691,1711,1581,1401,1251,0981,0921,0561,018989981968964945931
Shares Outstanding-0.7%74.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.0074.00--------
Float---28,200---22,300---26,500---16,742---9,218--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations3.9%239,100230,100169,200138,100230,800168,900173,100151,200160,800190,100144,40088,700148,700118,600148,10057,100106,400108,100105,10047,60073,200
  Share Based Compensation-76.3%1,4005,9007,5008,5006,7006,0005,5005,5009,95011,40010,3005,9006,35010,00012,3005,4005,6005,4007,2006,200400
Cashflow From Investing-13.7%-108,800-95,700-82,100-82,100-94,800-59,100-66,000-68,300-77,400-65,300-55,900-54,500-57,600-49,100-40,900-31,900-120,600-31,600-47,100-28,700-28,600
Cashflow From Financing-749.8%-189,500-22,300-176,800-71,000-9,500-75,200-36,200-172,700-6,200-5,800300-156,400-8,700-7,200-900-120,30051,000-4003,100-90,500-8,200
  Dividend Payments5.7%14,80014,00014,10014,10014,10013,50013,10013,40013,30012,60012,60012,60012,60011,90011,80011,80011,80011,10011,10011,10011,100
  Buy Backs536.7%177,00027,800173,40060,100-10027,20028,600147,100---137,100---115,500---83,100-

WST Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net sales$ 2,949.8$ 2,886.9$ 2,831.6
Cost of goods and services sold1,820.61,750.71,655.8
Gross profit1,129.21,136.21,175.8
Research and development68.458.552.8
Selling, general and administrative expenses353.4316.9362.8
Other expense (income) (Note 16)31.426.87.9
Operating profit676.0734.0752.3
Interest expense9.07.98.2
Interest income(28.0)(5.1)(1.0)
Other nonoperating (income) expense(3.0)51.3(3.8)
Income before income taxes and equity in net income of affiliated companies698.0679.9748.9
Income tax expense122.3114.7107.2
Equity in net income of affiliated companies(17.7)(20.7)(20.1)
Net income$ 593.4$ 585.9$ 661.8
Net income per share:   
Basic (in dollars per share)$ 7.98$ 7.87$ 8.89
Diluted (in dollars per share)$ 7.88$ 7.73$ 8.67
Weighted average shares outstanding:   
Basic (in shares)74.374.474.4
Diluted (in shares)75.375.876.3

WST Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 853.9$ 894.3
Accounts receivable, net512.0507.4
Inventories434.7414.8
Other current assets135.8103.0
Total current assets1,936.41,919.5
Property, plant and equipment2,738.02,386.6
Less: accumulated depreciation and amortization1,324.71,228.3
Property, plant and equipment, net1,413.31,158.3
Operating lease right-of-use assets99.2104.4
Investments in affiliated companies210.0204.9
Goodwill108.5107.3
Intangible assets, net15.118.4
Deferred income taxes25.765.6
Other noncurrent assets21.338.4
Total Assets3,829.53,616.8
Current liabilities:  
Notes payable and other current debt134.02.2
Accounts payable242.4215.4
Accrued salaries, wages and benefits105.976.8
Income taxes payable16.624.8
Operating lease liabilities17.716.0
Other current liabilities155.2183.8
Total current liabilities671.8519.0
Long-term debt72.8206.7
Deferred income taxes12.714.3
Pension and other postretirement benefits29.628.2
Operating lease liabilities84.593.0
Deferred compensation benefits18.619.1
Other long-term liabilities58.551.6
Total Liabilities948.5931.9
Commitments and contingencies (Note 18)
Equity:  
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2023 and 20220.00.0
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2023 and 2022; shares outstanding: 73.5 million and 74.1 million in 2023 and 202218.818.8
Capital in excess of par value120.2232.2
Retained earnings3,523.42,987.8
Accumulated other comprehensive loss(143.8)(183.0)
Treasury stock, at cost (1.8 million and 1.2 million shares in 2023 and 2022)(637.6)(370.9)
Total Equity2,881.02,684.9
Total Liabilities and Equity$ 3,829.5$ 3,616.8
WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
 CEO
 WEBSITEwestpharma.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES10700

West Pharmaceutical Services Inc Frequently Asked Questions


What is the ticker symbol for West Pharmaceutical Services Inc? What does WST stand for in stocks?

WST is the stock ticker symbol of West Pharmaceutical Services Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of West Pharmaceutical Services Inc (WST)?

As of Fri Apr 12 2024, market cap of West Pharmaceutical Services Inc is 27.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers.

What is the fair value of WST stock?

You can check WST's fair value in chart for subscribers. The fair value of West Pharmaceutical Services Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of West Pharmaceutical Services Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for WST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is West Pharmaceutical Services Inc a good stock to buy?

The fair value guage provides a quick view whether WST is over valued or under valued. Whether West Pharmaceutical Services Inc is cheap or expensive depends on the assumptions which impact West Pharmaceutical Services Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for WST.

What is West Pharmaceutical Services Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, WST's PE ratio (Price to Earnings) is 46.92 and Price to Sales (PS) ratio is 9.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. WST PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on West Pharmaceutical Services Inc's stock?

In the past 10 years, West Pharmaceutical Services Inc has provided 0.249 (multiply by 100 for percentage) rate of return.